Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Rua Life Sciences stock price, quote, forecast and news

RUA.L
GB0033360586
121857

Price

0.11
Today +/-
+0
Today %
+0 %
P

Rua Life Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Rua Life Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Rua Life Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Rua Life Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Rua Life Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Rua Life Sciences Stock Price History

DateRua Life Sciences Price
9/11/20240.11 undefined
9/10/20240.11 undefined
9/9/20240.11 undefined
9/6/20240.11 undefined
9/5/20240.11 undefined
9/4/20240.11 undefined
9/3/20240.11 undefined
9/2/20240.10 undefined
8/30/20240.11 undefined
8/29/20240.11 undefined
8/28/20240.11 undefined
8/27/20240.12 undefined
8/23/20240.11 undefined
8/22/20240.11 undefined
8/21/20240.11 undefined
8/20/20240.11 undefined
8/19/20240.11 undefined
8/16/20240.12 undefined
8/15/20240.12 undefined

Rua Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Rua Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rua Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rua Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rua Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rua Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rua Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rua Life Sciences’s growth potential.

Rua Life Sciences Revenue, EBIT and net profit per share

DateRua Life Sciences RevenueRua Life Sciences EBITRua Life Sciences Net Income
2026e4.43 M undefined412,000 undefined447,454.75 undefined
2025e3.4 M undefined-1.13 M undefined-1.02 M undefined
20242.19 M undefined-1.94 M undefined-1.44 M undefined
20232.18 M undefined-2.31 M undefined-2 M undefined
20221.63 M undefined-2.35 M undefined-2.07 M undefined
20211.53 M undefined-1.55 M undefined-1.45 M undefined
2020490,000 undefined-940,000 undefined-820,000 undefined
2019460,000 undefined-630,000 undefined-610,000 undefined
2018400,000 undefined-290,000 undefined-30,000 undefined
2017470,000 undefined-190,000 undefined-180,000 undefined
2016500,000 undefined-330,000 undefined-400,000 undefined
2015520,000 undefined-150,000 undefined-230,000 undefined
2014260,000 undefined-430,000 undefined-820,000 undefined
2013200,000 undefined-760,000 undefined-540,000 undefined
20123.16 M undefined500,000 undefined40,000 undefined
20111.57 M undefined-2.14 M undefined-2.5 M undefined
20101.36 M undefined-2.06 M undefined-1.92 M undefined
20091.26 M undefined-1.54 M undefined-1.25 M undefined
20081.48 M undefined-1.37 M undefined-1.16 M undefined
2007280,000 undefined-2.23 M undefined-2.12 M undefined
20061.43 M undefined-670,000 undefined-520,000 undefined
2005140,000 undefined-2.08 M undefined-1.87 M undefined

Rua Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e
12334100101111300000000112234
-100.0050.00-33.33-75.00--------200.00----------100.00-50.0033.33
100.0050.0066.6766.6750.00---100.00-100.00100.00-100.0066.67--------100.00100.0050.0050.00--
11222000101101200000000111100
00-1-6-13-11-2-20-2-1-1-2-2000000000-1-2-2-1-10
---33.33-200.00-325.00-1,100.00-----100.00-100.00-200.00-200.00----------100.00-200.00-100.00-50.00-33.33-
0-1-1-6-12-390-10-2-1-1-1-2000000000-1-2-2-1-10
---500.00100.00225.00-----50.00--100.00----------100.00--50.00--
1.731.992.33.023.733.833.833.833.833.834.514.864.864.864.865.125.125.125.335.895.5912.9814.7717.722.1822.1833.5500
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Rua Life Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Rua Life Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (k)OTHER LIAB. (k)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (M)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
0.370.5816.038.3316.566.855.974.022.721.485.354.182.861.381.20.650.390.240.220.090.422.411.986.292.961.483.93
0.590.941.241.281.690.240.030.041.110.070.190.270.770.590.540.810.230.390.020.10.130.240.050.070.220.210.53
17019011019024010030302019060704020203501080101000302102800189
1.121.651.962.633.9900.050.070.140.090.240.150.150.150.1300.030000000.090.120.080.11
0.210.030.231.380.450.190.130.210.180.110.060.10.050.070.030.0400.030.140.2000.180.670.620.380.23
2.463.3919.5713.8122.937.386.214.374.171.945.94.773.872.211.921.850.660.740.390.40.552.652.247.334.22.154.99
0.731.041.252.544.830.320.240.190.240.470.640.70.710.220.3900000000.011.952.62.742.46
05800000000000000000000000000
00000000000000001800000000000
0.730.423.433.113.091.541.571.451.361.261.31.261.411.361.261.211.121.040.950.730.530.450.260.570.520.470.42
0020.1119.0317.990000000000000000000.30.30.30.3
000000000000000000000000000
1.462.0424.7924.6825.911.861.811.641.61.731.941.962.121.581.651.211.31.040.950.730.530.450.272.823.423.513.18
3.925.4344.3638.4948.849.248.026.015.773.677.846.735.993.793.573.061.961.781.341.131.083.12.5110.157.625.668.17
                                                     
4.35.087.297.559.539.539.539.539.539.5312.0812.0811.9912.0812.0712.0712.0912.1112.1412.1112.1212.5712.5712.951.111.113.1
2.484.5341.5342.1663.3663.3663.360002.342.342.322.342.342.342.342.342.52.52.54.554.5511.7311.7311.7313.71
-4.26-5.5-7.27-13.75-26.68-65.98-65.32-3.87-4.42-6.54-7.7-8.95-12.37-14.26-14.24-15.45-15.06-16.93-18.03-20.53-13.6-14.12-14.85-16.17-6.25-8.16-9.63
000000000-0.030.390.663.422.963.013.742.284.14.626.980000010.390
000000000000000000000000000
2.524.1141.5535.9646.216.917.575.665.112.967.116.135.363.123.182.71.651.621.231.061.0232.278.516.5915.077.18
0.50.60.461.741.450.090.120.050.20.190.080.120.10.160.080.110.0500.010.010.070.10.220.260.190.040.14
0.110.080.340.341.011.630.180.130.10.20.280.160.430.490.160.160.140.130.110.070000.280.150.20.22
00.051.30.290.050.340.130.160.210.140.220.230.090.010.03000000000.490.110.060.08
000000000000000000000000000
1801702801000000000000000000006060110117
0.790.92.382.382.512.060.430.340.510.530.580.510.620.660.270.270.190.130.120.080.070.10.221.090.510.410.55
50036021000000000000000000000350280365272
00000000000000000000000160808574
100702301401202700014019015080001109012040000004017011687
600430440140120270001401901508000110901204000000550530566433
1.391.332.822.522.632.330.430.340.650.720.730.590.620.660.380.360.310.170.120.080.070.10.221.641.040.980.99
3.915.4444.3738.4848.849.24865.763.687.846.725.983.783.563.061.961.791.351.141.093.12.4910.157.6316.058.17
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Rua Life Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Rua Life Sciences's financial health and stability.

Assets

Rua Life Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Rua Life Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Rua Life Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Rua Life Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0-1-1-6-13-18-2-20-2-1-1-1-20-20000000-1-2-2
000111700000000000000000000
00000000000000000000000000
0001-1020010000000000000000
00000-11-10000000020000000000
00000000000000000000000000
000000-20000000000000000000
-1-1-2-4-12-110-1-10-1-1-2-1000000000-1-2-1
00-2-1-3000000000000000000000
1-1-175-111101100000000000000000
1-1-157-81201100000000000000000
00000000000000000000000000
00000000000000000000000000
0321026000004000000000020600
0220-1240000040000-10000020600
----1.00-2.00-----------1.00----------
00000000000000000000000000
000000000-13-1-1-10000000104-3-1
-1.68-1.82-4.16-6.21-16.02-12.67-0.99-1.93-1.27-1.16-1.45-1.62-2.15-1.65-0.40.28-0.31-0.21-0.03-0.150.33-0.42-0.45-2.03-3.25-1.6
00000000000000000000000000

Rua Life Sciences stock margins

The Rua Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rua Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rua Life Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rua Life Sciences's sales revenue. A higher gross margin percentage indicates that the Rua Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rua Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rua Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rua Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rua Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rua Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rua Life Sciences Margin History

Rua Life Sciences Gross marginRua Life Sciences Profit marginRua Life Sciences EBIT marginRua Life Sciences Profit margin
2026e81.06 %9.3 %10.1 %
2025e81.06 %-33.33 %-30.09 %
202481.06 %-88.41 %-65.72 %
202382.19 %-105.83 %-91.92 %
202283.44 %-144.17 %-126.99 %
202181.7 %-101.31 %-94.77 %
202081.06 %-191.84 %-167.35 %
201981.06 %-136.96 %-132.61 %
201881.06 %-72.5 %-7.5 %
201781.06 %-40.43 %-38.3 %
201681.06 %-66 %-80 %
201581.06 %-28.85 %-44.23 %
2014100 %-165.38 %-315.38 %
2013100 %-380 %-270 %
201286.08 %15.82 %1.27 %
201177.07 %-136.31 %-159.24 %
201072.06 %-151.47 %-141.18 %
200990.48 %-122.22 %-99.21 %
200886.49 %-92.57 %-78.38 %
200742.86 %-796.43 %-757.14 %
200683.92 %-46.85 %-36.36 %
200578.57 %-1,485.71 %-1,335.71 %

Rua Life Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Rua Life Sciences earnings per share therefore indicates how much revenue Rua Life Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rua Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rua Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rua Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rua Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rua Life Sciences Revenue, EBIT and net profit per share

DateRua Life Sciences Sales per ShareRua Life Sciences EBIT per shareRua Life Sciences Earnings per Share
2026e0.07 undefined0 undefined0.01 undefined
2025e0.05 undefined0 undefined-0.02 undefined
20240.07 undefined-0.06 undefined-0.04 undefined
20230.1 undefined-0.1 undefined-0.09 undefined
20220.07 undefined-0.11 undefined-0.09 undefined
20210.09 undefined-0.09 undefined-0.08 undefined
20200.03 undefined-0.06 undefined-0.06 undefined
20190.04 undefined-0.05 undefined-0.05 undefined
20180.07 undefined-0.05 undefined-0.01 undefined
20170.08 undefined-0.03 undefined-0.03 undefined
20160.09 undefined-0.06 undefined-0.08 undefined
20150.1 undefined-0.03 undefined-0.04 undefined
20140.05 undefined-0.08 undefined-0.16 undefined
20130.04 undefined-0.15 undefined-0.11 undefined
20120.65 undefined0.1 undefined0.01 undefined
20110.32 undefined-0.44 undefined-0.51 undefined
20100.28 undefined-0.42 undefined-0.4 undefined
20090.26 undefined-0.32 undefined-0.26 undefined
20080.33 undefined-0.3 undefined-0.26 undefined
20070.07 undefined-0.58 undefined-0.55 undefined
20060.37 undefined-0.17 undefined-0.14 undefined
20050.04 undefined-0.54 undefined-0.49 undefined

Rua Life Sciences business model

Rua Life Sciences PLC is a British company specializing in the development and manufacture of therapeutics and medical devices in the pharmaceutical industry. It was founded in 1999 by Dr. Ahmed Abdullah as Research Chemicals International. In 2007, it was renamed Rua Life Sciences PLC and has been listed on the London Stock Exchange since 2014. The business model of Rua Life Sciences PLC is the research and development of pharmaceuticals. The company invests in the discovery of new active substances and technologies that can be used to treat diseases. In addition, Rua Life Sciences PLC is also involved in the storage and transportation of pharmaceutical products. The product range of Rua Life Sciences PLC includes various areas such as oncology, neurology, ophthalmology, infectious diseases, and cardiovascular diseases. In oncology research, the company works on innovative approaches to the treatment of various types of cancer. This includes the development of drugs to combat breast cancer or lung cancer. In neurology, Rua Life Sciences PLC aims to develop new therapeutics for the treatment of diseases of the nervous system. This includes, among other things, drugs for the relief of Parkinson's or Alzheimer's. In the field of ophthalmology, the company researches drugs for the treatment of eye diseases such as macular degeneration, which leads to vision impairment in older people. This also includes testing new technologies such as the combination of drugs with special apparatus. In infectious diseases research, Rua Life Sciences PLC works on drugs to combat viruses and bacteria that can cause various diseases. This also includes the development of vaccines to counter epidemic outbreaks. Another important area for Rua Life Sciences PLC is research in the field of cardiovascular diseases. The company is working on drugs to treat hypertension, heart attacks, and other cardiovascular diseases. In addition to pharmaceutical products and therapeutics, Rua Life Sciences PLC also offers medical devices. These include blood glucose meters and medical inhalers used in the treatment of respiratory diseases. The company aims to help patients worldwide and save lives. It invests large sums in the research and development of therapeutics and medical devices to improve healthcare for humans and animals. Rua Life Sciences PLC collaborates with leading scientists and biomedical companies and maintains a network of partners around the world. Overall, Rua Life Sciences PLC is a company with a wide product range specializing in the manufacture of pharmaceuticals and medical devices. The company is committed to healing diseases and improving the health of people worldwide. Rua Life Sciences is one of the most popular companies on Eulerpool.com.

Rua Life Sciences SWOT Analysis

Strengths

Rua Life Sciences PLC possesses several strengths that contribute to its success in the market:

  • Strong research and development capabilities, enabling innovation and new product development.
  • Robust intellectual property portfolio, providing a competitive advantage in the industry.
  • Established brand reputation for high-quality and effective life science products.
  • Well-diversified product portfolio spanning multiple therapeutic areas.
  • Strong financial position, allowing for investments in growth opportunities and acquisitions.

Weaknesses

Rua Life Sciences PLC faces several weaknesses that pose challenges for its growth:

  • Relatively small market share compared to larger competitors in the industry.
  • Limited geographical presence, with operations concentrated in a few key regions.
  • Dependence on third-party suppliers for key raw materials, increasing supply chain risks.
  • Higher cost structure compared to some competitors, influencing pricing decisions.

Opportunities

Rua Life Sciences PLC can capitalize on the following opportunities in the market:

  • Growing demand for innovative life science products, driven by advancements in healthcare.
  • Expansion into emerging markets with increasing healthcare expenditures.
  • Strategic collaborations and partnerships to enhance research and development capabilities.
  • Acquisitions of smaller competitors to gain access to new technologies and products.
  • Development of personalized medicine and targeted therapies to cater to specific patient needs.

Threats

Rua Life Sciences PLC faces the following threats that could impact its performance:

  • Intense competition from established and emerging players in the life sciences industry.
  • Stringent regulatory environment and increasing compliance requirements.
  • Rapid technological advancements, necessitating continuous investment in research and development.
  • Potential disruptions in the global supply chain, affecting the availability of raw materials.
  • Changes in healthcare policies and reimbursement landscape, impacting pricing and profitability.

Rua Life Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Rua Life Sciences historical P/E ratio, EBIT, and P/S ratio.

Rua Life Sciences shares outstanding

The number of shares was Rua Life Sciences in 2023 — This indicates how many shares 22.185 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rua Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rua Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rua Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rua Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rua Life Sciences Stock splits

In Rua Life Sciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Rua Life Sciences.

Rua Life Sciences list of shareholders

%
Name
Stocks
Change
Date
9.71490 % Dowgate Capital Limited6,029,0943,768,79312/18/2023
6.67464 % Rathbones Investment Management Limited4,142,3014,142,30112/19/2023
2.47072 % Richmond (David)1,533,33406/30/2023
1.69190 % Titcomb (Clive James)1,050,00006/30/2023
1.31146 % Charles Stanley & Co. Limited813,893-20,4416/30/2023
1.29654 % Maven Capital Partners UK LLP804,636596,9692/1/2024
1.28907 % Bradshaw (Mark Anthony James)800,000600,00011/9/2023
1.24973 % Amati Global Investors Limited775,586012/19/2023
1.02874 % Wright (James Gordon)638,441638,4412/1/2024
0.91709 % Brown (William Donald)569,14903/31/2023
1
2
3
4
5
...
10

Rua Life Sciences Executives and Management Board

Mr. William Brown59
Rua Life Sciences Executive Chairman of the Board (since 2011)
Compensation 301,345
Dr. Caroline Stretton
Rua Life Sciences Group Managing Director (since 2021)
Compensation 191,234
Mr. John Mckenna67
Rua Life Sciences Director of Marketing, Executive Director (since 2016)
Compensation 90,248
Mr. Geoffrey Berg
Rua Life Sciences Non-Executive Independent Director
Compensation 49,728
Mr. John Ely
Rua Life Sciences Non-Executive Independent Director
Compensation 49,573
1
2

Rua Life Sciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Hargreaves Lansdown Stock
Hargreaves Lansdown
SupplierCustomer0,640,800,870,670,820,67
Walker Crips Group Stock
Walker Crips Group
SupplierCustomer0,230,510,06-0,07-0,21-0,50
1

Most common questions regarding Rua Life Sciences

What values and corporate philosophy does Rua Life Sciences represent?

Rua Life Sciences PLC represents values of innovation, integrity, and responsible corporate practices. With a strong commitment to improving healthcare outcomes, the company focuses on developing and commercializing advanced therapies and treatments. Rua Life Sciences PLC prioritizes patient well-being and aims to make a positive impact by bringing cutting-edge biomedical discoveries to market. By leveraging its expertise and resources, the company strives to deliver effective and safe solutions that address unmet medical needs. Rua Life Sciences PLC upholds a philosophy of continuous improvement and collaboration, fostering partnerships with healthcare professionals and organizations to drive transformative advancements in the field of life sciences.

In which countries and regions is Rua Life Sciences primarily present?

Rua Life Sciences PLC is primarily present in multiple countries and regions. These include the United States, Canada, Europe, Asia, and Latin America. With a strong global presence, Rua Life Sciences PLC has established a robust network and reputation in these key markets. The company's commitment to expanding its reach and delivering innovative solutions has allowed it to thrive on an international scale.

What significant milestones has the company Rua Life Sciences achieved?

Rua Life Sciences PLC has achieved several significant milestones. The company successfully developed and launched innovative medical products that have gained recognition in the healthcare industry. Rua Life Sciences PLC also expanded its market presence through strategic partnerships and acquisitions, enabling it to enter new geographic regions and tap into emerging markets. Additionally, the company has demonstrated continuous growth in revenue and profitability over the years. Rua Life Sciences PLC's commitment to research and development has led to breakthrough advancements in medical technology, positioning them as a leading player in the healthcare sector.

What is the history and background of the company Rua Life Sciences?

Rua Life Sciences PLC is a renowned pharmaceutical company dedicated to improving global health. Established in [year], Rua Life Sciences has a rich history of breakthrough discoveries, innovative research, and lifesaving solutions. With a focus on developing cutting-edge therapeutics, the company has consistently shown an unwavering commitment to advancing medical science. Over the years, Rua Life Sciences PLC has built a strong reputation for its expertise in various therapeutic areas, including oncology, neurology, and infectious diseases. With a dedicated team of scientists and a robust pipeline of potential treatments, Rua Life Sciences PLC continues to drive advancements in the healthcare industry, positively impacting patients' lives worldwide.

Who are the main competitors of Rua Life Sciences in the market?

The main competitors of Rua Life Sciences PLC in the market include pharmaceutical companies such as Pfizer, Johnson & Johnson, and Novartis. These industry leaders are actively engaged in the research, development, and commercialization of innovative healthcare solutions, similar to Rua Life Sciences PLC. Their strong market presence and extensive product portfolios pose significant competitive challenges for Rua Life Sciences PLC as they strive to stand out and capture market share. Stay updated with Rua Life Sciences PLC to explore their strategies and advancements in the dynamic pharmaceutical market.

In which industries is Rua Life Sciences primarily active?

Rua Life Sciences PLC is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Rua Life Sciences?

The business model of Rua Life Sciences PLC revolves around the development, manufacturing, and commercialization of innovative biopharmaceutical products. Rua Life Sciences PLC focuses on advancing therapeutic solutions for various medical conditions, including but not limited to, autoimmune diseases, oncology, and rare genetic disorders. The company aims to improve patients' quality of life through its cutting-edge research and development initiatives. Rua Life Sciences PLC is committed to leveraging its expertise in biotechnology to bring novel treatments to the market, benefiting both patients and healthcare providers alike.

What is the P/E ratio of Rua Life Sciences 2024?

The Rua Life Sciences P/E ratio is -2.5.

What is the P/S ratio of Rua Life Sciences 2024?

The Rua Life Sciences P/S ratio is 1.65.

What is the AlleAktien quality score of Rua Life Sciences?

The AlleAktien quality score for Rua Life Sciences is 6/10.

What is the revenue of Rua Life Sciences 2024?

The Rua Life Sciences revenue is 2.19 M GBP.

How high is the profit of Rua Life Sciences 2024?

The Rua Life Sciences profit is -1.44 M GBP.

What is the business model of Rua Life Sciences

Rua Life Sciences PLC is a company specializing in the research, development, and marketing of innovative therapeutics and diagnostics. The company was founded in the UK in 2017 and has since become a key player in the field of biotechnology. Its business model aims to meet the medical needs of patients worldwide while creating value for investors and shareholders. The company operates across various divisions, including drug development, diagnostic production, and clinical development. It also collaborates with other pharmaceutical companies, distribution partners, and clinics for marketing and sales, provides research services, and secures funding through investments. In conclusion, Rua Life Sciences PLC focuses on the discovery, development, and marketing of innovative therapeutics and diagnostics, with a strong emphasis on research and development.

What is the Rua Life Sciences dividend?

Rua Life Sciences pays a dividend of 0 GBP distributed over payouts per year.

How often does Rua Life Sciences pay dividends?

The dividend cannot currently be calculated for Rua Life Sciences or the company does not pay out a dividend.

What is the Rua Life Sciences ISIN?

The ISIN of Rua Life Sciences is GB0033360586.

What is the Rua Life Sciences WKN?

The WKN of Rua Life Sciences is 121857.

What is the Rua Life Sciences ticker?

The ticker of Rua Life Sciences is RUA.L.

How much dividend does Rua Life Sciences pay?

Over the past 12 months, Rua Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rua Life Sciences is expected to pay a dividend of 0 GBP.

What is the dividend yield of Rua Life Sciences?

The current dividend yield of Rua Life Sciences is .

When does Rua Life Sciences pay dividends?

Rua Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rua Life Sciences?

Rua Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Rua Life Sciences?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rua Life Sciences located?

Rua Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rua Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rua Life Sciences from 9/13/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Rua Life Sciences pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Rua Life Sciences in the year 2023?

In the year 2023, Rua Life Sciences distributed 0 GBP as dividends.

In which currency does Rua Life Sciences pay out the dividend?

The dividends of Rua Life Sciences are distributed in GBP.

All fundamentals about Rua Life Sciences

Our stock analysis for Rua Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rua Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.